GrantForecasted — not yet open✓ Small businesses may apply
Evaluating the Cutaneous Pharmacokinetics of Topical Drug Products Using Pharmacokinetic Tomography (U01 Clinical Trial Required)
Food and Drug Administration
Award ceiling
$250,000
Award floor
$250,000
- Opportunity #
- FOR-FD-24-004
- Agency
- Food and Drug Administration
- ALN (CFDA)
- 93.103
- Status
- forecasted
- Posted
- Nov 24, 2023
- Funding instrument
- Cooperative Agreement
- Category
- Agriculture, Consumer Protection, Food and Nutrition
- Cost sharing required
- No
Who can apply
- •City or township governments
- •Small businesses
- •Special district governments
- •Public and State controlled institutions of higher education
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Public housing authorities/Indian housing authorities
- •Private institutions of higher education
- •Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
- •County governments
- •For profit organizations other than small businesses
- •State governments
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •Independent school districts
- •Native American tribal governments (Federally recognized)
Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).
Contact
Terrin Brown Grantor · terrin.brown@fda.hhs.gov